Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel Free NMRA Stock Alerts

Neumora Therapeutics (NMRA) Financials

Neumora Therapeutics logo
$1.33 -0.06 (-4.32%)
Closing price 08/31/2026 04:00 PM Eastern
Extended Trading
$1.38 +0.05 (+4.14%)
As of 07:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Neumora Therapeutics

Annual Income Statements for Neumora Therapeutics

This table shows Neumora Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -131 -236 -244 -237
Consolidated Net Income / (Loss)		 -131 -236 -244 -237
Net Income / (Loss) Continuing Operations		 -131 -236 -244 -237
Total Pre-Tax Income 		-131 -236 -244 -237
Total Operating Income		 -136 -252 -263 -241
Total Gross Profit		 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00
Total Operating Expenses		 136 252 263 241
Selling, General & Admin Expense		 31 45 63 60
Research & Development Expense		 105 207 201 181
Total Other Income / (Expense), net		 4.97 16 20 4.36
Interest Expense		 - - 0.00 3.22
Interest & Investment Income		 4.56 17 20 8.34
Other Income / (Expense), net		 0.41 -0.17 -0.08 -0.77
Income Tax Expense		 0.00 0.27 0.18 0.13
Basic Earnings per Share		 ($4.81) ($3.63) ($1.53) ($1.45)
Weighted Average Basic Shares Outstanding		 27.21M 65.02M 159.38M 163.39M
Diluted Earnings per Share		 ($4.81) ($3.63) ($1.53) ($1.45)
Weighted Average Diluted Shares Outstanding		 27.21M 65.02M 159.38M 163.39M
Weighted Average Basic & Diluted Shares Outstanding		 - 158.89M 161.98M 182.04M

Quarterly Income Statements for Neumora Therapeutics

This table shows Neumora Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Total Costs & Expenses		 - - - - - - 54 - - - 42
Net Income / (Loss) Attributable to Common Shareholders		 -109 -54 -59 -73 -59 -68 -53 -57 -59 -53 -43
Consolidated Net Income / (Loss)		 -109 -54 -59 -73 -59 -68 -53 -57 -59 -53 -43
Net Income / (Loss) Continuing Operations		 -109 -54 -59 -73 -59 -68 -53 -57 -59 -53 -43
Total Pre-Tax Income 		-144 -54 -59 -72 -113 -68 -53 -57 -59 -53 -43
Total Operating Income		 -114 -60 -64 -77 -63 -71 -54 -58 -58 -53 -42
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 114 60 64 77 63 71 54 58 58 53 42
Selling, General & Admin Expense		 11 14 15 16 17 19 15 12 14 14 13
Research & Development Expense		 103 46 49 61 46 52 39 46 45 39 29
Total Other Income / (Expense), net		 5.54 6.35 5.25 4.15 4.10 3.05 1.33 0.95 -0.97 -0.56 -0.89
Interest Expense		 - - - 0.00 - 0.00 0.44 0.75 - 1.85 1.82
Interest & Investment Income		 5.65 6.37 5.27 4.21 4.09 3.07 2.25 1.69 1.77 1.23 0.94
Other Income / (Expense), net		 -0.10 -0.01 -0.02 -0.06 0.02 -0.03 -0.48 0.01 -0.27 0.06 -0.01
Income Tax Expense		 0.27 0.00 0.13 0.05 - 0.11 0.03 0.00 - 0.03 0.00
Basic Earnings per Share		 $0.01 ($0.34) ($0.37) ($0.45) ($0.37) ($0.42) ($0.33) ($0.35) ($0.35) ($0.30) ($0.23)
Weighted Average Basic Shares Outstanding		 65.02M 157.94M 158.98M 159.58M 159.38M 161.45M 161.69M 161.84M 163.39M 179.87M 185.16M
Diluted Earnings per Share		 $0.01 ($0.34) ($0.37) ($0.45) ($0.37) ($0.42) ($0.33) ($0.35) ($0.35) ($0.30) ($0.23)
Weighted Average Diluted Shares Outstanding		 65.02M 157.94M 158.98M 159.58M 159.38M 161.45M 161.69M 161.84M 163.39M 179.87M 185.16M
Weighted Average Basic & Diluted Shares Outstanding		 158.89M 159.52M 160.03M 161.56M 161.98M 161.75M 161.95M 167.09M 182.04M 185.28M 187.90M

Annual Cash Flow Statements for Neumora Therapeutics

This table details how cash moves in and out of Neumora Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -167 133 -232 39
Net Cash From Operating Activities		 -115 -163 -183 -206
Net Cash From Continuing Operating Activities		 -115 -163 -183 -208
Net Income / (Loss) Continuing Operations		 -131 -236 -244 -237
Consolidated Net Income / (Loss)		 -131 -236 -244 -237
Depreciation Expense		 0.59 0.67 0.63 0.21
Amortization Expense		 - - 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 22 81 38 30
Changes in Operating Assets and Liabilities, net		 -6.95 -8.90 23 -0.44
Net Cash From Investing Activities		 -168 64 -71 169
Net Cash From Continuing Investing Activities		 -168 64 -71 169
Acquisitions		 -13 -4.59 -0.78 0.00
Purchase of Investments		 -226 -109 -312 -83
Sale of Property, Plant & Equipment		 - - 0.00 0.22
Sale and/or Maturity of Investments		 72 178 242 251
Net Cash From Financing Activities		 116 232 22 77
Net Cash From Continuing Financing Activities		 116 232 22 77
Issuance of Debt		 - - 0.00 57
Issuance of Common Equity		 0.00 233 14 20
Other Financing Activities, net		 3.53 -0.95 7.48 0.00
Cash Interest Paid		 - - 0.00 1.50
Cash Income Taxes Paid		 0.00 0.00 0.47 0.32

Quarterly Cash Flow Statements for Neumora Therapeutics

This table details how cash moves in and out of Neumora Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -38 -191 -32 125 -134 -15 -3.55 4.55 53 -35 -30
Net Cash From Operating Activities		 -51 -43 -56 -33 -50 -59 -52 -47 -48 -46 -40
Net Cash From Continuing Operating Activities		 -51 -43 -56 -33 -50 -59 -52 -47 -49 -46 -40
Net Income / (Loss) Continuing Operations		 -109 -54 -59 -73 -59 -68 -53 -57 -59 -53 -43
Consolidated Net Income / (Loss)		 -109 -54 -59 -73 -59 -68 -53 -57 -59 -53 -43
Depreciation Expense		 0.17 0.16 0.16 0.16 0.16 0.16 0.02 0.02 0.01 0.01 0.01
Amortization Expense		 - - - - - 0.00 - 2.70 -0.52 0.42 0.39
Non-Cash Adjustments To Reconcile Net Income		 70 6.22 12 6.99 12 8.00 9.37 2.73 9.42 7.39 7.11
Changes in Operating Assets and Liabilities, net		 -13 4.39 -9.84 32 -3.84 0.39 -6.65 4.44 1.38 -0.77 -3.95
Net Cash From Financing Activities		 -0.48 1.85 2.65 1.53 16 0.00 18 -0.14 59 11 9.29
Net Cash From Continuing Financing Activities		 -0.48 1.85 2.65 1.53 16 0.00 18 -0.14 59 11 9.29
Issuance of Common Equity		 - 0.00 - - 14 0.00 0.06 - 20 11 -11
Other Financing Activities, net		 -3.47 1.85 2.65 1.76 1.23 0.00 - - - 0.00 20

Annual Balance Sheets for Neumora Therapeutics

This table presents Neumora Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 426 496 317 191
Total Current Assets		 388 478 314 191
Cash & Equivalents		 241 374 142 183
Restricted Cash		 0.05 0.00 1.21 0.00
Short-Term Investments		 131 80 165 0.00
Prepaid Expenses		 16 24 5.26 8.01
Plant, Property, & Equipment, net		 2.41 1.79 1.14 0.04
Total Noncurrent Assets		 36 16 1.78 0.47
Long-Term Investments		 24 9.85 - 0.00
Other Noncurrent Operating Assets		 12 6.28 1.78 0.47
Total Liabilities & Shareholders' Equity		 426 496 317 191
Total Liabilities		 29 27 30 87
Total Current Liabilities		 24 25 30 32
Accounts Payable		 7.15 0.34 3.31 3.38
Accrued Expenses		 12 21 25 29
Other Current Liabilities		 5.01 3.52 1.99 0.28
Total Noncurrent Liabilities		 5.70 2.01 0.02 55
Long-Term Debt		 - - 0.00 55
Other Noncurrent Operating Liabilities		 5.70 2.01 0.02 0.19
Commitments & Contingencies		 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -447 469 287 104
Total Preferred & Common Equity		 -447 469 287 104
Total Common Equity		 -447 469 287 104
Common Stock		 21 1,173 1,234 1,288
Retained Earnings		 -468 -703 -947 -1,184
Accumulated Other Comprehensive Income / (Loss)		 -0.77 -0.08 0.06 0.00

Quarterly Balance Sheets for Neumora Therapeutics

This table presents Neumora Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 450 404 353 257 224 178 154 125
Total Current Assets		 443 398 349 255 223 177 153 125
Cash & Equivalents		 183 151 276 127 125 129 147 117
Restricted Cash		 0.00 0.00 1.21 1.21 0.00 0.00 0.00 0.00
Short-Term Investments		 240 221 66 122 93 42 0.00 0.00
Prepaid Expenses		 20 27 6.09 4.30 5.32 5.56 6.36 8.04
Plant, Property, & Equipment, net		 1.64 1.48 1.30 0.98 0.09 0.08 0.03 0.03
Total Noncurrent Assets		 5.79 4.68 2.63 0.90 0.83 0.67 0.41 0.35
Long-Term Investments		 0.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Assets		 5.49 4.68 2.63 0.90 0.83 0.67 0.41 0.35
Total Liabilities & Shareholders' Equity		 450 404 353 257 224 178 154 125
Total Liabilities		 26 23 32 28 41 46 83 81
Total Current Liabilities		 25 23 32 28 21 26 30 28
Accounts Payable		 1.49 1.08 6.11 1.05 0.64 0.55 5.06 4.15
Accrued Expenses		 19 18 23 26 20 25 25 23
Other Current Liabilities		 3.62 3.74 2.88 1.06 0.26 0.31 0.29 0.30
Total Noncurrent Liabilities		 1.06 0.09 0.06 0.00 20 20 53 53
Long-Term Debt		 - - - - 19 20 53 53
Other Noncurrent Operating Liabilities		 1.06 0.09 0.06 0.00 0.34 0.27 0.12 0.04
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 425 381 321 228 183 132 71 45
Total Preferred & Common Equity		 425 381 321 228 183 132 71 45
Total Common Equity		 425 381 321 228 183 132 71 45
Common Stock		 1,182 1,197 1,209 1,244 1,251 1,257 1,308 1,325
Retained Earnings		 -757 -816 -888 -1,015 -1,068 -1,125 -1,238 -1,281
Accumulated Other Comprehensive Income / (Loss)		 -0.15 -0.19 0.11 -0.00 -0.02 0.01 0.00 0.00

Annual Metrics And Ratios for Neumora Therapeutics

This table displays calculated financial ratios and metrics derived from Neumora Therapeutics' official financial filings.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 - 167,089,114.00
DEI Adjusted Shares Outstanding		 0.00 0.00 - 167,089,114.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 - -1.42
Growth Metrics		 - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -86.55% -4.50% 8.06%
EBIT Growth		 0.00% -86.22% -4.47% 8.20%
NOPAT Growth		 0.00% -85.54% -4.51% 8.47%
Net Income Growth		 0.00% -80.23% -3.33% 2.81%
EPS Growth		 0.00% 24.53% 57.85% 5.23%
Operating Cash Flow Growth		 0.00% -42.11% -12.04% -12.85%
Free Cash Flow Firm Growth		 0.00% 0.00% 12.69% -5.69%
Invested Capital Growth		 0.00% 277.08% -513.93% -11.05%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 16.30% 1.63%
EBIT Q/Q Growth		 0.00% 0.00% 16.27% 1.69%
NOPAT Q/Q Growth		 0.00% 0.00% 16.24% 1.81%
Net Income Q/Q Growth		 0.00% 0.00% 16.99% -0.27%
EPS Q/Q Growth		 0.00% 0.00% -33.04% 1.36%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.60% 1.14%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 4.31%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.25% -21.85%
Profitability Metrics		 - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.11% 100.07% 100.05%
Interest Burden Percent		 96.63% 93.42% 92.44% 97.88%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -32.99% -54.49% -64.48% -121.21%
Cash Return on Invested Capital (CROIC)		 0.00% -5,430.68% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 37.14% -1.40% -64.48% -121.21%
Return on Equity Simple (ROE_SIMPLE)		 29.29% -50.30% -84.92% 0.00%
Net Operating Profit after Tax (NOPAT)		 -95 -176 -184 -169
NOPAT Margin		 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -9.05% -13.84% -15.37% -31.19%
Return On Investment Capital (ROIC_SIMPLE)		 21.28% -37.62% -64.25% -106.57%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -135 -252 -264 -242
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -135 -252 -263 -242
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 0.00 0.00 5.97 2.88
Price to Tangible Book Value (P/TBV)		 0.00 0.00 5.97 2.88
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 501.66 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 0.00 0.00 0.00 0.53
Long-Term Debt to Equity		 0.00 0.00 0.00 0.53
Financial Leverage		 -1.00 -0.99 -1.02 -1.12
Leverage Ratio		 1.07 1.07 1.08 1.30
Compound Leverage Factor		 1.04 1.00 0.99 1.27
Debt to Total Capital		 0.00% 0.00% 0.00% 34.43%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 34.43%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 212.60% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -112.60% 100.00% 100.00% 65.57%
Debt to EBITDA		 0.00 0.00 0.00 -0.23
Net Debt to EBITDA		 0.00 0.00 0.00 0.53
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.23
Debt to NOPAT		 0.00 0.00 0.00 -0.32
Net Debt to NOPAT		 0.00 0.00 0.00 0.76
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.32
Altman Z-Score		 3.55 0.00 28.50 -9.80
Noncontrolling Interest Sharing Ratio		 212.60% 97.43% 0.00% 0.00%
Liquidity Ratios		 - - - -
Current Ratio		 16.37 19.05 10.51 5.87
Quick Ratio		 15.69 18.08 10.29 5.62
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -180 -157 -166
Operating Cash Flow to CapEx		 -22,484.54% -139,553.85% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -51.70
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -64.13
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -64.06
Efficiency Ratios		 - - - -
Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - -
Invested Capital		 1.39 5.25 -22 -24
Invested Capital Turnover		 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 3.86 -27 -2.40
Enterprise Value (EV)		 698 0.00 1,404 171
Market Capitalization		 250 0.00 1,713 299
Book Value per Share		 ($16.42) $7.21 $1.78 $0.62
Tangible Book Value per Share		 ($16.42) $7.21 $1.78 $0.62
Total Capital		 397 469 287 158
Total Debt		 0.00 0.00 0.00 55
Total Long-Term Debt		 0.00 0.00 0.00 55
Net Debt		 -395 -464 -309 -128
Capital Expenditures (CapEx)		 0.51 0.12 0.00 -0.22
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.68 -0.81 -25 -24
Debt-free Net Working Capital (DFNWC)		 364 453 284 158
Net Working Capital (NWC)		 364 453 284 158
Net Nonoperating Expense (NNE)		 36 59 59 68
Net Nonoperating Obligations (NNO)		 -395 -464 -309 -128
Total Depreciation and Amortization (D&A)		 0.59 0.67 0.63 0.21
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 $0.00 ($3.63) ($1.53) ($1.45)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 65.02M 159.38M 163.39M
Adjusted Diluted Earnings per Share		 $0.00 ($3.63) ($1.53) ($1.45)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 65.02M 159.38M 163.39M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 158.89M 161.98M 182.04M
Normalized Net Operating Profit after Tax (NOPAT)		 -95 -176 -184 -169
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -75.15
NOPAT to Interest Expense		 0.00 0.00 0.00 -52.44
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -75.09
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -52.37
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Neumora Therapeutics

This table displays calculated financial ratios and metrics derived from Neumora Therapeutics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 0.00 158,886,101.00 159,523,997.00 160,027,746.00 - 161,978,923.00 161,747,922.00 161,945,427.00 167,089,114.00 182,040,945.00 185,284,244.00
DEI Adjusted Shares Outstanding		 0.00 158,886,101.00 159,523,997.00 160,027,746.00 - 161,978,923.00 161,747,922.00 161,945,427.00 167,089,114.00 182,040,945.00 185,284,244.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -0.34 -0.37 -0.45 - -0.42 -0.33 -0.35 -0.36 -0.29 -0.23
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -53.52% -51.89% -35.02% 44.93% -18.15% 14.42% 28.19% 5.57% 26.02% 22.88%
EBIT Growth		 0.00% -53.30% -51.65% -34.89% 44.87% -18.10% 14.61% 24.78% 6.61% 25.59% 22.60%
NOPAT Growth		 0.00% -53.38% -51.73% -34.79% 44.81% -18.08% 15.33% 24.72% 7.06% 25.48% 21.93%
Net Income Growth		 0.00% -50.80% -52.30% -36.81% 45.90% -26.57% 10.17% 21.77% -1.07% 21.38% 18.30%
EPS Growth		 0.00% 72.13% 71.09% 60.53% -3,800.00% -23.53% 10.81% 22.22% 5.41% 28.57% 30.30%
Operating Cash Flow Growth		 0.00% -30.01% -81.03% 29.91% 2.14% -38.40% 6.68% -39.27% 4.74% 21.94% 24.57%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 40.50% 76.15% -32.94% -125.76% -37.99% -96.05%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% -513.93% -1,555.87% -258.61% 9.09% -11.05% -5.53% -27.17%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -100.98% 47.40% -6.27% -20.19% 18.02% -12.84% 23.03% -0.86% -7.80% 11.61% 20.20%
EBIT Q/Q Growth		 -100.66% 47.34% -6.26% -20.14% 17.99% -12.80% 23.17% -5.82% -1.83% 10.12% 20.09%
NOPAT Q/Q Growth		 -100.49% 47.31% -6.24% -20.09% 17.91% -12.74% 23.82% -6.77% -1.35% 9.60% 20.19%
Net Income Q/Q Growth		 -105.05% 50.59% -9.27% -23.59% 18.92% -15.60% 22.45% -7.63% -4.75% 10.08% 19.41%
EPS Q/Q Growth		 100.88% -3,500.00% -8.82% -21.62% 17.78% -13.51% 21.43% -6.06% 0.00% 14.29% 23.33%
Operating Cash Flow Q/Q Growth		 -7.68% 16.50% -30.74% 40.38% -50.35% -18.09% 11.85% 11.01% -2.83% 3.23% 14.82%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -24.60% 41.30% 46.44% -51.90% 50.05% -227.18% 9.05% 7.16% 29.04%
Invested Capital Q/Q Growth		 0.00% -70.95% 530.82% -326.41% 0.25% -2.19% 31.28% -29.77% -21.85% 2.89% 17.18%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 75.46% 100.00% 100.21% 100.07% 52.27% 100.15% 100.05% 100.00% 100.00% 100.06% 100.00%
Interest Burden Percent		 126.27% 89.41% 91.74% 94.51% 178.90% 95.67% 96.67% 98.37% 101.19% 101.18% 102.10%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -54.49% -59.83% -71.91% -183.14% -64.48% -79.05% -89.37% -104.35% -121.21% -148.74% -187.11%
Cash Return on Invested Capital (CROIC)		 -3,435.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -1.40% -59.83% -71.91% -183.14% -64.48% -79.05% -89.37% -104.35% -121.21% -148.74% -187.11%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -59.83% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -80 -42 -45 -54 -44 -50 -38 -40 -41 -37 -30
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -6.24% -5.52% -7.55% -11.03% -3.82% -5.44% -5.23% -6.62% -8.48% -9.55% -10.34%
Return On Investment Capital (ROIC_SIMPLE)		 -17.01% -9.91% -11.72% -16.73% -15.34% -21.74% -18.70% -26.62% -25.84% -29.93% -30.31%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -114 -60 -64 -77 -63 -71 -55 -58 -59 -53 -42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -114 -60 -64 -77 -63 -71 -55 -55 -59 -52 -42
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 5.15 4.11 6.59 5.97 0.71 0.65 2.23 2.88 5.02 7.08
Price to Tangible Book Value (P/TBV)		 0.00 5.15 4.11 6.59 5.97 0.71 0.65 2.23 2.88 5.02 7.08
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 1,155.19 124.37 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.11 0.15 0.53 0.75 1.19
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.11 0.15 0.53 0.75 1.19
Financial Leverage		 -0.99 -1.00 -0.97 -1.07 -1.02 -1.03 -1.01 -1.09 -1.12 -1.15 -1.15
Leverage Ratio		 1.07 1.06 1.06 1.10 1.08 1.08 1.11 1.17 1.30 1.37 1.54
Compound Leverage Factor		 1.35 0.95 0.97 1.04 1.92 1.04 1.08 1.15 1.32 1.39 1.57
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 9.61% 12.89% 34.43% 42.84% 54.31%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 9.61% 12.89% 34.43% 42.84% 54.31%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 90.39% 87.11% 65.57% 57.16% 45.69%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.07 -0.08 -0.23 -0.24 -0.25
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.75 0.62 0.53 0.42 0.30
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.07 -0.08 -0.23 -0.24 -0.25
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.11 -0.11 -0.32 -0.34 -0.36
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 1.07 0.88 0.76 0.60 0.43
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.11 -0.11 -0.32 -0.34 -0.36
Altman Z-Score		 0.00 49.39 38.30 36.72 30.59 -1.97 -4.66 -5.03 -6.64 -8.87 -12.16
Noncontrolling Interest Sharing Ratio		 97.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 19.05 17.99 17.22 10.98 10.51 8.98 10.54 6.85 5.87 5.09 4.50
Quick Ratio		 18.08 17.18 16.07 10.75 10.29 8.79 10.28 6.64 5.62 4.88 4.21
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -44 -54 -32 -17 -26 -13 -42 -39 -36 -25
Operating Cash Flow to CapEx		 -116,913.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -56.72 0.00 -19.30 -13.95
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -62.43 0.00 -25.03 -21.72
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -62.31 0.00 -24.99 -21.72
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 5.25 1.53 9.62 -22 -22 -22 -15 -20 -24 -23 -19
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 1.53 9.62 -22 -27 -24 -25 1.98 -2.40 -1.23 -4.15
Enterprise Value (EV)		 0.00 1,762 1,196 1,771 1,404 -89 -80 143 171 261 251
Market Capitalization		 0.00 2,185 1,568 2,114 1,713 162 119 295 299 355 315
Book Value per Share		 $7.21 $2.67 $2.39 $2.00 $1.78 $1.41 $1.13 $0.82 $0.62 $0.39 $0.24
Tangible Book Value per Share		 $7.21 $2.67 $2.39 $2.00 $1.78 $1.41 $1.13 $0.82 $0.62 $0.39 $0.24
Total Capital		 469 425 381 321 287 228 202 152 158 124 97
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 19 20 55 53 53
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 19 20 55 53 53
Net Debt		 -464 -423 -372 -343 -309 -251 -198 -152 -128 -94 -64
Capital Expenditures (CapEx)		 0.04 0.00 0.00 0.00 0.00 0.00 0.00 -0.09 -0.05 -0.07 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.81 -4.54 3.56 -26 -25 -24 -16 -20 -24 -24 -20
Debt-free Net Working Capital (DFNWC)		 453 418 375 317 284 226 202 151 158 123 97
Net Working Capital (NWC)		 453 418 375 317 284 226 202 151 158 123 97
Net Nonoperating Expense (NNE)		 29 12 14 19 15 18 15 16 19 16 14
Net Nonoperating Obligations (NNO)		 -464 -423 -372 -343 -309 -251 -198 -152 -128 -94 -64
Total Depreciation and Amortization (D&A)		 0.17 0.16 0.16 0.16 0.16 0.16 0.02 2.72 -0.51 0.43 0.40
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.01 ($0.34) ($0.37) ($0.45) ($0.37) ($0.42) ($0.33) ($0.35) ($0.35) ($0.30) ($0.23)
Adjusted Weighted Average Basic Shares Outstanding		 65.02M 157.94M 158.98M 159.58M 159.38M 161.45M 161.69M 161.84M 163.39M 179.87M 185.16M
Adjusted Diluted Earnings per Share		 $0.01 ($0.34) ($0.37) ($0.45) ($0.37) ($0.42) ($0.33) ($0.35) ($0.35) ($0.30) ($0.23)
Adjusted Weighted Average Diluted Shares Outstanding		 65.02M 157.94M 158.98M 159.58M 159.38M 161.45M 161.69M 161.84M 163.39M 179.87M 185.16M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 158.89M 159.52M 160.03M 161.56M 161.98M 161.75M 161.95M 167.09M 182.04M 185.28M 187.90M
Normalized Net Operating Profit after Tax (NOPAT)		 -80 -42 -45 -54 -44 -50 -38 -40 -41 -37 -30
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -77.23 0.00 -28.48 -23.19
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -54.07 0.00 -19.96 -16.23
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -77.12 0.00 -28.44 -23.19
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -53.95 0.00 -19.92 -16.23
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Neumora Therapeutics (NASDAQ: NMRA) remains a pre-revenue biotech with a very large cash balance, but the latest quarter also shows continued heavy operating losses and cash burn. The company ended Q1 2026 with $147.1 million in cash and equivalents and $153.9 million in total assets, versus $83.2 million in total liabilities, leaving $70.7 million in common equity.

Compared with prior periods, the balance sheet has improved from a liquidity standpoint in the near term because cash is still substantial. However, the bigger trend over the last several quarters is that Neumora continues to consume cash quickly while funding research and development. In Q1 2026, the company generated no revenue, posted a $53.5 million net loss, and used $46.4 million in operating cash flow.

  • Cash remains significant: Neumora ended Q1 2026 with $147.1 million in cash and equivalents, giving it runway for ongoing development work.
  • Current assets exceed current liabilities: Total current assets of $153.4 million were above current liabilities of $30.1 million, which suggests near-term liquidity is manageable.
  • Debt is lower than it was in late 2025: Long-term debt was $52.96 million in Q1 2026, down from $59.96 million at year-end 2025 and far below the spike seen in 2025 Q3/Q4.
  • Operating cash outflow improved slightly quarter over quarter: Net cash from operations was -$46.4 million in Q1 2026 versus -$49.2 million in Q4 2025.
  • No revenue yet: The company still reported $0 in revenue, so progress is entirely dependent on clinical and pipeline execution.
  • Large R&D spend continues: Research and development expense was $38.6 million in Q1 2026, showing management is still heavily investing in the pipeline.
  • Share count has increased over time: Basic weighted average shares rose to 179.9 million in Q1 2026 from 161.5 million in Q1 2025, reflecting dilution.
  • Quarterly losses remain large: Net loss was $53.5 million in Q1 2026, only modestly better than the $59.5 million loss in Q4 2025.
  • Cash burn is still substantial: The company used $46.4 million in operating cash in Q1 2026, which is a major drain on liquidity.
  • Balance sheet has weakened versus last year: Total assets fell from $256.7 million in Q1 2025 to $153.9 million in Q1 2026, while equity dropped from $228.4 million to $70.7 million.

Looking at the broader trend over the last four years, Neumora has transitioned from a much larger cash position in early 2024 to a much leaner one today. Total cash and short-term investments were well above $400 million in early 2024, but the company has since burned through capital through persistent losses and operating outflows. That means investors should focus less on earnings quality and more on cash runway, trial progress, and financing risk.

Bottom line: NMRA still has enough cash to keep operating in the near term, but the financial profile remains high-risk. The key question for investors is whether upcoming pipeline milestones can justify the ongoing burn before the company needs additional financing.

09/01/26 05:00 AM ETAI Generated. May Contain Errors.

Neumora Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Neumora Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Neumora Therapeutics' net income appears to be on an upward trend, with a most recent value of -$236.93 million in 2025, rising from -$130.90 million in 2022. The previous period was -$243.79 million in 2024. Check out Neumora Therapeutics' forecast to explore projected trends and price targets.

Neumora Therapeutics' total operating income in 2025 was -$241.16 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $241.16 million

Over the last 3 years, Neumora Therapeutics' total revenue changed from $0.00 in 2022 to $0.00 in 2025, a change of 0.0%.

Neumora Therapeutics' total liabilities were at $87.18 million at the end of 2025, a 191.5% increase from 2024, and a 196.5% increase since 2022.

In the past 3 years, Neumora Therapeutics' cash and equivalents has ranged from $142.15 million in 2024 to $374.04 million in 2023, and is currently $182.53 million as of their latest financial filing in 2025.

Over the last 3 years, Neumora Therapeutics' book value per share changed from -16.42 in 2022 to 0.62 in 2025, a change of -103.8%.


Related Companies

Financial statements for NASDAQ:NMRA last updated on 8/14/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel